For the 2022 reporting year, the following ASCO-developed measures are available in the Merit-based Incentive Payment System (MIPS) reporting program. The CMS QPP website lists the complete MIPS Oncology Measures Set. To view the Measures Set, select Oncology/Hematology from the Speciality Measure Set dropdown list. The CMS MIPS historical quality benchmarks for ASCO MIPS measures are available here. 

MIPS Clinical Quality Measures (CQMs) and electronic Clinical Quality Measures (eCQMs)

These oncology measures are available for reporting to CMS in the MIPS Program.

Quality ID

(QPP/NQF)

Measure Title

QPP 143

(NQF 0384)

 Oncology: Medical and Radiation-Pain Intensity Quantified (CQM)

CMS157v10

(NQF 0384e)

Oncology Medical and Radiation-Pain Intensity Quantified (eCQM)

QPP 144

(NQF 0383)

 Oncology: Medical and Radiation-Plan of Care for Pain (CQM)

QPP 450

(NQF 1858)

Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer (CQM)

QPP 451

(NQF 1859)

RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy (CQM)

QPP 452

(NQF 1860)

Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (CQM)

QPP 453

(NQF 0210)

Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better) (CQM)

QPP 457

(NQF 0216)

Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better) (CQM)